In its phase 3 clinical trial results, Bharat Biotech's Covaxin showed 77.8 percent efficacy against symptomatic COVID-19, the manufacturer of the indigenous vaccine said in a statement.The company has also stated that Covaxin has demonstrated 93.4 percent effusiveness against severe symptomatic COVID and 65.2 percent against the Delta variant. The vaccine was found to offer 63.6 percent protection against asymptomatic COVID-19.

In its phase 3 clinical trial results, Bharat Biotech's Covaxin showed 77.8 percent efficacy against symptomatic COVID-19, the manufacturer of the indigenous vaccine said in a statement.The company has also stated that Covaxin has demonstrated 93.4 percent effusiveness against severe symptomatic COVID and 65.2 percent against the Delta variant. The vaccine was found to offer 63.6 percent protection against asymptomatic COVID-19.